Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurobiology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTN ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed to preserve native glycosylation and heparin-binding conformation. |
View PTN Products |
| Gene Delivery | PTN Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional overexpression assays. |
View PTN Products |
| Benchmark Ab | Anti-PTN Recombinant Antibody Recombinant positive control derived from clinical-grade benchmark sequences for validation. |
View PTN Products |
| Validator | PTN siRNA Set For target knockdown verification and target specificity validation in cell-based assays. |
View PTN Products |
| Related Target A | MDK (Midkine) Closest family homolog to PTN. Essential for counter-screening to ensure drug specificity and eliminate off-target heparin-binding effects. |
View MDK Products |
| Related Target B | ALK (Anaplastic Lymphoma Kinase) Key functional receptor for PTN signaling in glioblastoma and neuroblastoma pathways. |
View ALK Products |
| Related Target C | PTPRZ1 (RPTPβ/ζ) Receptor protein tyrosine phosphatase that binds PTN to regulate cell migration and stemness. |
View PTPRZ1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heparin-binding interference | High-purity recombinant PTN with intact heparin-binding domains, verified by strict chromatography to avoid batch-to-batch variation. |
| Homolog cross-reactivity (MDK) | Recombinant Midkine (MDK) panel available for rigorous counter-screening and selectivity profiling. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and sequence-verified positive controls included. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification in functional assays. |
Live PTN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTN therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific biologicals and small molecule inhibitors targeting the PTN-ALK and PTN-PTPRZ1 axes. As first-generation therapies targeting tumor angiogenesis reach the clinic, the next wave of R&D is targeting the tumor microenvironment, macrophage polarization, and therapeutic resistance in glioblastoma and pancreatic ductal adenocarcinoma (PDAC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic Institutes, Oncology Biotech | Glioblastoma, Pancreatic Cancer | Blocking Assay (Need sequence-verified PTN recombinant proteins) |
| Small Molecule Inhibitors | Global Pharma, Biotech | Neuroblastoma, Solid Tumors | Binding Affinity/Selectivity Assay (Need PTN vs. MDK counter-screening panels) |
| siRNA / RNAi | RNA Therapeutics Specialists | Advanced Solid Tumors, Fibrosis | In vitro knockdown validation (Need validated siRNA transfection controls) |